Abstract
The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy
-
Aspergillosis / microbiology
-
Aspergillus fumigatus / drug effects*
-
Female
-
Humans
-
Immunosuppressive Agents
-
Liposomes / administration & dosage
-
Liposomes / therapeutic use*
-
Lung Diseases, Fungal / drug therapy*
-
Lung Diseases, Fungal / microbiology
-
Nebulizers and Vaporizers*
-
Rats
-
Rats, Wistar
-
Steroids
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Immunosuppressive Agents
-
Liposomes
-
Steroids
-
Amphotericin B